P

Inventor

HAVIV FORTUNA

US50 patents
⚠️ This page may combine multiple inventors who share the name “HAVIV FORTUNA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ABBOTT LAB

28 patents
US5110904AMay 5, 1992

Lhrh analogs

ABBOTT LAB61 citations96
US4476137AOct 9, 1984

[1-(2-Benzoxazolyl)hydrazino]alkyl nitrile derivatives

ABBOTT LAB68 citations92
US4407803AOct 4, 1983

Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives

ABBOTT LAB67 citations92
US6020521AFeb 1, 2000

Macrolide LHRH antagonists

ABBOTT LAB45 citations89
US6716963B1Apr 6, 2004

Peptide antiangiogenic drugs

ABBOTT LAB15 citations83
US5955440ASep 21, 1999

Macrolide LHRH antagonists

ABBOTT LAB19 citations82
US6774211B1Aug 10, 2004

Peptide antiangiogenic drugs

ABBOTT LAB10 citations73
US5432263AJul 11, 1995

Process for producing peptides with side chains containing imidazolinylamino, tetrahydropyrimidinylamino, or alkylguanidinyl groups

ABBOTT LAB11 citations73
US6191115B1Feb 20, 2001

C-terminus modified heptapeptide LHRH analogs

ABBOTT LAB7 citations72
US5981521ANov 9, 1999

Tetrahydroisoquinoline derivatives as LHRH antagonists

ABBOTT LAB11 citations72
US5516647AMay 14, 1996

Compounds useful as alkaline phosphatase inhibitors and therapeutic agents

ABBOTT LAB10 citations71
US4312887AJan 26, 1982

2-Hydroxylaminomethyl phenols

ABBOTT LAB3 citations63
US6777535B1Aug 17, 2004

N-alkylated peptides having antiangiogenic activity

ABBOTT LAB3 citations62
US4489084ADec 18, 1984

[1-(2-Oxazolyl) or -(2-thiazolyl) hydrazino]alkyl nitriles

ABBOTT LAB4 citations61
US6387885B1May 14, 2002

3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists

ABBOTT LAB4 citations60
US5972898AOct 26, 1999

3',3-N-bis-substituted macrolide LHRH antagonists

ABBOTT LAB4 citations60
US4370339AJan 25, 1983

Method for treating inflammatory conditions

ABBOTT LAB3 citations59
US6297354B1Oct 2, 2001

Pentapeptide LHRH antagonists

ABBOTT LAB6 citations57
US7067490B2Jun 27, 2006

Hepta-, Octa-and nonapeptides having antiangiogenic activity

ABBOTT LAB1 citations52
US7001984B2Feb 21, 2006

Di-, tri-, and tetra-peptides having antiangiogenic activity

ABBOTT LAB1 citations52
US4273940AJun 16, 1981

Bis-(2-benzylaminoethyl)-disulfides

ABBOTT LAB0 citations52
US5698522ADec 16, 1997

6-position modified decapeptide LHRH antagonists

ABBOTT LAB1 citations51
US4503056AMar 5, 1985

1-(Pyridazinyl)pyrazoline derivatives

ABBOTT LAB1 citations50
US7432245B2Oct 7, 2008

Pharmaceutical formulation comprising a peptide angiogenesis inhibitor

ABBOTT LAB0 citations42
US7592466B2Sep 22, 2009

Ureas having antiangiogenic activity

ABBOTT LAB0 citations41
US7169888B2Jan 30, 2007

Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity

ABBOTT LAB0 citations41
US7122625B2Oct 17, 2006

Hexa-, hepta-, and octapeptides having antiangiogenic activity

ABBOTT LAB0 citations41
US7037897B2May 2, 2006

TRI-, TETRA-, and penta-peptides having antiangiogenic activity

ABBOTT LAB0 citations41

YEDA RES & DEV

14 patents

TAP HOLDINGS INC

3 patents

TAP PHARMACEUTICALS INC

2 patents

TAP PHARMACEUTICALS

1 patent

(unassigned)

1 patent

TAP HOLDING INC

1 patent